Paolo Fogagnolo, Giulia Torregrossa, Laura Tranchina, Antonio Ferreras, Stefano De Cillá, Antoine Labbé*, Michele Figus, Laura Ottobelli and Luca Rossetti Pages 4241 - 4252 ( 12 )
Glaucoma is the second leading cause of blindness in the world, affecting more than 60 million people globally. In order to reduce the progression of the disease, both medical and surgical treatments are used. Frequent side effects of both treatments include a range of modifications of the ocular surface grouped as the Ocular Surface Disease (OSD), which include Dry Eye Disease (DED). DED and other OSD negatively impact on the success of anti-glaucoma treatments and reduce the adherence to medical therapies. Tear film osmolarity (TFO) is a relatively novel test which has become a hallmark of DED. The aim of this paper was to review the association between OSD, DED and glaucoma in view of published TFO data, and to discuss future fields of research and treatments on the topic of glaucoma iatrogenic damage.
Tear film osmolarity, glaucoma, benzalkonium chloride, ocular surface disease, dry eye disease, blindness.
Eye Clinic, San Paolo Hospital, University of Milan, Milan, Eye Clinic, San Paolo Hospital, University of Milan, Milan, Eye Clinic, San Paolo Hospital, University of Milan, Milan, Department of Ophthalmology, Miguel Servet University Hospital, University of Zaragoza, Zaragoza, Unit of Ophthalmology, Ospedale Maggiore della Carita, Novara, Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, Vision Institute, Versailles Saint-Quentin en Yvelines University, 75012 Paris, Ophthalmology, Department of Neurosciences, University of Pisa, Pisa, Eye Clinic, San Paolo Hospital, University of Milan, Milan, Eye Clinic, San Paolo Hospital, University of Milan, Milan